Show simple item record

dc.contributor.authorKramer, Tilmann
dc.contributor.authorVentovuori, Ville
dc.contributor.authorHeinonen, Ari
dc.contributor.authorParkkari, Jari
dc.contributor.authorKorhonen, Marko T
dc.contributor.authorRovio, Anja
dc.contributor.authorHoenemann, Jan-Niklas
dc.contributor.authorMöstl, Stefan
dc.contributor.authorSies, Wolfram
dc.contributor.authorKaiser-Stolz, Claudia
dc.contributor.authorChilibeck, Philip
dc.contributor.authorTanaka, Hirofumi
dc.contributor.authorKramer, Mira
dc.contributor.authorRittweger, Joern
dc.contributor.authorHautala, Arto J
dc.date.accessioned2024-09-04T10:08:05Z
dc.date.available2024-09-04T10:08:05Z
dc.date.issued2024
dc.identifier.citationKramer, T., Ventovuori, V., Heinonen, A., Parkkari, J., Korhonen, M. T., Rovio, A., Hoenemann, J.-N., Möstl, S., Sies, W., Kaiser-Stolz, C., Chilibeck, P., Tanaka, H., Kramer, M., Rittweger, J., & Hautala, A. J. (2024). Prevalence of electrocardiographic markers associated with myocardial fibrosis in masters athletes : a cohort study. <i>BMJ Open Sport & Exercise Medicine</i>, <i>10</i>(3), e001988. <a href="https://doi.org/10.1136/bmjsem-2024-001988" target="_blank">https://doi.org/10.1136/bmjsem-2024-001988</a>
dc.identifier.otherCONVID_242548683
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/96923
dc.description.abstractObjectives Myocardial fibrosis (MF) is associated with an increased predisposition to adverse cardiac events. The accumulation of high-volume and high-intensity exercise over an extended duration potentially increases the risk of MF. Specific electrocardiographic markers have been correlated with the presence of MF. This study assessed the prevalence of MF-related electrocardiographic markers in a Track and Field Master Athletics Cohort (TaFMAC). Methods Twelve-lead resting electrocardiograms (ECGs) were conducted on 155 athletes (90 males and 65 females) participating in the World Masters Athletics 2022. The ECG markers associated with MF, including pathological Q waves, inverted T waves, fragmented QRS complex, and prolonged QRS complex, were compared among different athletic specialities (endurance athletes n=51, sprinters n=69 and strength and power n=35). Results Overall, 71 instances of MF-related markers were identified from 155 ECG recordings (46%). Fragmented QRS emerged as the most common marker, with a prevalence of 29% in endurance and strength and power athletes, and 35% in sprinters. No significant group differences were observed in the prevalence of MF markers, whether analysed collectively (p=0.467) or individually (pathological Q waves p=0.367, inverted T waves p=0.309, fragmented QRS complex p=0.747 and prolonged QRS complex p=0.132). Conclusions The prevalence of MF markers, as determined by resting ECG, was evident in nearly half of masters athletes, irrespective of sex and sporting specialisation. These findings suggest resting ECG as a promising non-invasive method for the early identification of MF in athlete’s hearts.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofseriesBMJ Open Sport & Exercise Medicine
dc.rightsCC BY-NC 4.0
dc.titlePrevalence of electrocardiographic markers associated with myocardial fibrosis in masters athletes : a cohort study
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202409045810
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerangee001988
dc.relation.issn2055-7647
dc.relation.numberinseries3
dc.relation.volume10
dc.type.versionpublishedVersion
dc.rights.copyright© Author(s) (or their employer(s)) 2024
dc.rights.accesslevelopenAccessfi
dc.subject.ysoyleisurheilu
dc.subject.ysoEKG
dc.subject.ysourheilu
dc.subject.ysourheilijat
dc.subject.ysoharjoittelu
dc.subject.ysosydäntaudit
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p935
jyx.subject.urihttp://www.yso.fi/onto/yso/p20204
jyx.subject.urihttp://www.yso.fi/onto/yso/p965
jyx.subject.urihttp://www.yso.fi/onto/yso/p3315
jyx.subject.urihttp://www.yso.fi/onto/yso/p26412
jyx.subject.urihttp://www.yso.fi/onto/yso/p2710
dc.rights.urlhttps://creativecommons.org/licenses/by-nc/4.0/
dc.relation.doi10.1136/bmjsem-2024-001988
jyx.fundinginformationThe primary sponsor of the TaFMAC study was the German Aerospace Center (DLR) - Institute of Aerospace Medicine, Department of Muscle and Bone Metabolism, Linder Höhe, 51147 Cologne, Germany. No additional financial support was received for this study. TK was supported by the Cologne Clinician Scientist Program (CCSP)/Faculty of Medicine/University of Cologne, funded by the German Research Foundation (DFG, Project No. 413543196).
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY-NC 4.0
Except where otherwise noted, this item's license is described as CC BY-NC 4.0